Florence T Bourgeois

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1340269/publications.pdf

Version: 2024-02-01

115	3,818	33 h-index	56
papers	citations		g-index
119	119	119	5599
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Improving FDA postmarket adverse event reporting for medical devices. BMJ Evidence-Based Medicine, 2023, 28, 83-84.	3.5	O
2	A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 191-198.	1.3	5
3	National assessment of anti-epileptic drug exposures among pre-teens and adolescents, 2000–2020. Clinical Toxicology, 2022, 60, 681-687.	1.9	3
4	OUP accepted manuscript. Journal of the Pediatric Infectious Diseases Society, 2022, , .	1.3	0
5	Identifying unreported links between ClinicalTrials.gov trial registrations and their published results. Research Synthesis Methods, 2022, 13, 342-352.	8.7	4
6	National Institutes of Health Funding Priorities—Reply. JAMA Pediatrics, 2022, 176, 325.	6.2	0
7	Trends in Benzodiazepine Prescribing for US Adolescents and Young Adults From 2008 to 2019. JAMA Pediatrics, 2022, 176, 312.	6.2	5
8	Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis. Clinical Trials, 2022, 19, 442-451.	1.6	5
9	Clinical development of new drugs for adults and children with cancer in 2010-2020: Longitudinal study of investigational drugs Journal of Clinical Oncology, 2022, 40, 1563-1563.	1.6	O
10	Development and Validation of a Pediatric Comorbidity Index. American Journal of Epidemiology, 2021, 190, 918-927.	3.4	33
11	Dynamic Dossier in the Cloud: A SociotechnicalÂArchitecture for a Real-Time and Metrics-Based Data Tracking System with Gene and Cell TherapiesÂas a Case Study. Therapeutic Innovation and Regulatory Science, 2021, 55, 388-400.	1.6	0
12	Antidiabetic medication use in <scp>commercially insured</scp> children and adolescents in the United States from 2004 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 444-454.	4.4	2
13	Association of Selective Serotonin Reuptake Inhibitors With the Risk of Type 2 Diabetes in Children and Adolescents. JAMA Psychiatry, 2021, 78, 91.	11.0	22
14	Analysis of SteraMist ionized hydrogen peroxide technology in the sterilization of N95 respirators and other PPE. Scientific Reports, 2021, 11, 2051.	3.3	34
15	Evaluation of Publication of Pediatric Drug Trials. JAMA Network Open, 2021, 4, e215829.	5.9	3
16	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. JAMA Network Open, 2021, 4, e2112596.	5.9	33
17	National Trends in Disease Activity for COVID-19 Among Children in the US. Frontiers in Pediatrics, 2021, 9, 700656.	1.9	3
18	Assessing the filtration efficiency and regulatory status of N95s and nontraditional filtering face-piece respirators available during the COVID-19 pandemic. BMC Infectious Diseases, 2021, 21, 712.	2.9	16

#	Article	IF	Citations
19	Trends in Gabapentin and Pregabalin Prescribing in a Tertiary Pediatric Medical Center. Hospital Pediatrics, 2021, 11, 909-914.	1.3	3
20	Correlation Between National Institutes of Health Funding for Pediatric Research and Pediatric Disease Burden in the US. JAMA Pediatrics, 2021, 175, 1236.	6.2	16
21	Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children. JAMA Oncology, 2021, 7, 1281.	7.1	4
22	Factors Associated With Corticosteroid Treatment for Pediatric Acute Respiratory Tract Infections. Journal of the Pediatric Infectious Diseases Society, 2021, , .	1.3	0
23	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. Scientific Reports, 2021, 11, 20238.	3.3	10
24	The automation of relevant trial registration screening for systematic review updates: an evaluation study on a large dataset of ClinicalTrials.gov registrations. BMC Medical Research Methodology, 2021, 21, 281.	3.1	3
25	The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system. Genetics in Medicine, 2020, 22, 371-380.	2.4	30
26	Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. Journal of the National Cancer Institute, 2020, 112, 224-228.	6.3	16
27	Pediatric Drug Policies Supporting Safe And Effective Use Of Therapeutics In Children: A Systematic Analysis. Health Affairs, 2020, 39, 1799-1805.	5.2	17
28	Landscape of phase 1 clinical trials for minors with cancer in the United States. Pediatric Blood and Cancer, 2020, 67, e28694.	1.5	7
29	Association of State-Level Opioid-Reduction Policies With Pediatric Opioid Poisoning. JAMA Pediatrics, 2020, 174, 961.	6.2	17
30	Incompletely Reported Important Methodological Details and Inaccurate Description of the Formulation That the Control Arms Received in a Gardasil Vaccine Trial. MSphere, 2020, 5, .	2.9	2
31	The urgent need for research coordination to advance knowledge on COVID-19 in children. Pediatric Research, 2020, 90, 250-252.	2.3	6
32	Is it time for computable evidence synthesis?. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 972-975.	4.4	12
33	Inclusion of Children in Clinical Trials of Treatments for Coronavirus Disease 2019 (COVID-19). JAMA Pediatrics, 2020, 174, 825.	6.2	28
34	Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. BMJ Evidence-Based Medicine, 2020, 25, 213-219.	3.5	7
35	Personal Protective Equipment for COVID-19: Distributed Fabrication and Additive Manufacturing. American Journal of Public Health, 2020, 110, 1162-1164.	2.7	35
36	Offâ€label use of prescription analgesics among hospitalized children in the United States. Pharmacoepidemiology and Drug Safety, 2020, 29, 474-481.	1.9	6

#	Article	IF	Citations
37	Developing a pediatric pain data repository. JAMIA Open, 2020, 3, 31-36.	2.0	6
38	Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials. JAMA - Journal of the American Medical Association, 2020, 323, 1903.	7.4	9
39	Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Medicine, 2020, 9, 4495-4500.	2.8	9
40	Improving Pediatric Academic Global Health Collaborative Research and Agenda Setting: A Mixed-Methods Study. American Journal of Tropical Medicine and Hygiene, 2020, 102, 649-657.	1.4	15
41	Importance of authorship and inappropriate authorship assignment in paediatric research in low―and middle―ncome countries. Tropical Medicine and International Health, 2019, 24, 1229-1242.	2.3	18
42	Prescription opioid use and misuse among adolescents and young adults in the United States: AÂnational survey study. PLoS Medicine, 2019, 16, e1002922.	8.4	146
43	Promoting Pediatric Drug Research and Labeling — Outcomes of Legislation. New England Journal of Medicine, 2019, 381, 875-881.	27.0	19
44	Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases. Health Affairs, 2019, 38, 313-319.	5.2	19
45	Trends in Opioid Prescribing for Adolescents and Young Adults in Ambulatory Care Settings. Pediatrics, 2019, 143, .	2.1	35
46	A Recurrent Missense Variant in AP2M1 Impairs Clathrin-Mediated Endocytosis and Causes Developmental and Epileptic Encephalopathy. American Journal of Human Genetics, 2019, 104, 1060-1072.	6.2	78
47	Trial2rev: Combining machine learning and crowd-sourcing to create a shared space for updating systematic reviews. JAMIA Open, 2019, 2, 15-22.	2.0	20
48	Cost Implications of Escalating Intravenous Acetaminophen Use in Children. JAMA Pediatrics, 2019, 173, 489.	6.2	11
49	The timing and frequency of trial inclusion in systematic reviews of typeÂ2 diabetes drugs was associated with trial characteristics. Journal of Clinical Epidemiology, 2019, 109, 62-69.	5.0	3
50	Neglected tropical diseases in children: An assessment of gaps in research prioritization. PLoS Neglected Tropical Diseases, 2019, 13, e0007111.	3.0	23
51	The use of opioids in low acuity pediatric trauma patients. PLoS ONE, 2019, 14, e0226433.	2.5	4
52	Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis. PLoS Medicine, 2019, 16, e1002966.	8.4	52
53	Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act. JAMA Pediatrics, 2019, 173, 68.	6.2	36
54	Improving the Study of New Medicines for Children With Rare Diseases. JAMA Pediatrics, 2018, 172, 7.	6.2	6

#	Article	IF	CITATIONS
55	Availability of paediatric information in European Medicines Agency approvals. The Lancet Child and Adolescent Health, 2018, 2, e9.	5. 6	2
56	Prevalence of Disclosed Conflicts of Interest in Biomedical Research and Associations With Journal Impact Factors and Altmetric Scores. JAMA - Journal of the American Medical Association, 2018, 319, 408.	7.4	52
57	Variation in Pediatric Procedural Sedations Across Children's Hospital Emergency Departments. Hospital Pediatrics, 2018, 8, 36-43.	1.3	13
58	Unreported links between trial registrations and published articles were identified using document similarity measures in a cross-sectional analysis of ClinicalTrials.gov. Journal of Clinical Epidemiology, 2018, 95, 94-101.	5.0	11
59	A shared latent space matrix factorisation method for recommending new trial evidence for systematic review updates. Journal of Biomedical Informatics, 2018, 79, 32-40.	4.3	14
60	Variation in the evaluation of testicular conditions across United States pediatric emergency departments. American Journal of Emergency Medicine, 2018, 36, 208-212.	1.6	8
61	Pediatric drug information available at the time of new drug approvals: A crossâ€sectional analysis. Pharmacoepidemiology and Drug Safety, 2018, 27, 161-167.	1.9	25
62	Registration of published randomized trials: a systematic review and meta-analysis. BMC Medicine, 2018, 16, 173.	5 . 5	53
63	Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study. PLoS Medicine, 2018, 15, e1002520.	8.4	46
64	The Pediatric Research Equity Act Moves Into Adolescence. JAMA - Journal of the American Medical Association, 2017, 317, 259.	7.4	38
65	Complexity and Severity of Pediatric Patients Treated at United States Emergency Departments. Journal of Pediatrics, 2017, 186, 145-149.e1.	1.8	56
66	Exclusion of Elderly People from Randomized Clinical Trials of Drugs for Ischemic Heart Disease. Journal of the American Geriatrics Society, 2017, 65, 2354-2361.	2.6	63
67	The Evolution of Patient Diagnosis. JAMA - Journal of the American Medical Association, 2017, 318, 1859.	7.4	30
68	Conclusions in systematic reviews of mammography for breast cancer screening and associations with review design and author characteristics. Systematic Reviews, 2017, 6, 105.	5. 3	17
69	Development of the Precision Link Biobank at Boston Children's Hospital: Challenges and Opportunities. Journal of Personalized Medicine, 2017, 7, 21.	2.5	20
70	A systematic review of the processes used to link clinical trial registrations to their published results. Systematic Reviews, 2017, 6, 123.	5. 3	37
71	Emergency Department Management of Febrile Respiratory Illness in Children. Pediatric Emergency Care, 2016, 32, 429-434.	0.9	17
72	Measuring patient-perceived quality of care in US hospitals using Twitter. BMJ Quality and Safety, 2016, 25, 404-413.	3.7	130

#	Article	IF	CITATIONS
73	Drug-Drug Interactions Among Hospitalized Children Receiving Chronic Antiepileptic Drug Therapy. Hospital Pediatrics, 2016, 6, 282-289.	1.3	10
74	Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children. Pediatrics, 2016, 138, .	2.1	124
7 5	Effect of Randomized Clinical Trial Findings on Emergency Management. Academic Emergency Medicine, 2016, 23, 36-47.	1.8	5
76	Financial competing interests were associated with favorable conclusions and greater author productivity in nonsystematic reviews of neuraminidase inhibitors. Journal of Clinical Epidemiology, 2016, 80, 43-49.	5.0	6
77	Conflict of interest disclosure in biomedical research: a review of current practices, biases, and the role of public registries in improving transparency. Research Integrity and Peer Review, 2016, 1, .	5.2	118
78	Prevalence and Characteristics of Interventional Trials Conducted Exclusively in Elderly Persons: A Cross-Sectional Analysis of Registered Clinical Trials. PLoS ONE, 2016, 11, e0155948.	2.5	20
79	Industry-sponsored clinical research outside high-income countries: an empirical analysis of registered clinical trials from 2006 to 2013. Health Research Policy and Systems, 2015, 13, 28.	2.8	20
80	Variation and Trends in Charges for Pediatric Care in Massachusetts Emergency Departments, 2000–2011. Academic Emergency Medicine, 2015, 22, 1164-1171.	1.8	3
81	Comparison of Drug Utilization Patterns in Observational Data: Antiepileptic Drugs in Pediatric Patients. Paediatric Drugs, 2015, 17, 401-410.	3.1	17
82	Citations alone were enough to predict favorable conclusions in reviews of neuraminidase inhibitors. Journal of Clinical Epidemiology, 2015, 68, 87-93.	5.0	10
83	Identifying Clinical Study Types from PubMed Metadata: The Active (Machine) Learning Approach. Studies in Health Technology and Informatics, 2015, 216, 867-71.	0.3	O
84	Premarket Safety and Efficacy Studies for ADHD Medications in Children. PLoS ONE, 2014, 9, e102249.	2.5	11
85	Drug Safety in the Digital Age. New England Journal of Medicine, 2014, 370, 2460-2462.	27.0	21
86	Financial Conflicts of Interest and Conclusions About Neuraminidase Inhibitors for Influenza. Annals of Internal Medicine, 2014, 161, 513.	3.9	68
87	New Regulatory Paradigms for Innovative Drugs to Treat Pediatric Diseases. JAMA Pediatrics, 2014, 168, 879.	6.2	3
88	Use of QTâ€prolonging medications in US emergency departments, 1995–2009. Pharmacoepidemiology and Drug Safety, 2014, 23, 9-17.	1.9	24
89	Variation in Emergency Department Admission Rates in US Children's Hospitals. Pediatrics, 2014, 134, 539-545.	2.1	63
90	Postmarketing Trials and Pediatric Device Approvals. Pediatrics, 2014, 133, e1197-e1202.	2.1	39

#	Article	IF	Citations
91	Association Between Pediatric Clinical Trials and Global Burden of Disease. Pediatrics, 2014, 133, 78-87.	2.1	42
92	Industry influence in evidence production. Journal of Epidemiology and Community Health, 2013, 67, 537-538.	3.7	2
93	Adult Prescription Drug Use and Pediatric Medication Exposures and Poisonings. Pediatrics, 2013, 132, 18-27.	2.1	104
94	Analysis of Pediatric Clinical Drug Trials for Neuropsychiatric Conditions. Pediatrics, 2013, 131, 1125-1131.	2.1	9
95	The Effects of Industry Sponsorship on Comparator Selection in Trial Registrations for Neuropsychiatric Conditions in Children. PLoS ONE, 2013, 8, e84951.	2.5	16
96	Pediatric Versus Adult Drug Trials for Conditions With High Pediatric Disease Burden. Pediatrics, 2012, 130, 285-292.	2.1	115
97	The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics. Clinical Pharmacology and Therapeutics, 2012, 91, 685-691.	4.7	10
98	Comparative Effectiveness Research: An Empirical Study of Trials Registered in ClinicalTrials.gov. PLoS ONE, 2012, 7, e28820.	2.5	24
99	Factors Associated With the Use of Cervical Spine Computed Tomography Imaging in Pediatric Trauma Patients. Academic Emergency Medicine, 2011, 18, 905-911.	1.8	26
100	The Effect of Funding Source on Outcome Reporting Among Drug Trials. Annals of Internal Medicine, 2011, 154, 138.	3.9	0
101	Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov. Annals of Internal Medicine, 2010, 153, 158.	3.9	299
102	Adverse drug events in the outpatient setting: an 11â€year national analysis. Pharmacoepidemiology and Drug Safety, 2010, 19, 901-910.	1.9	260
103	Neuroimaging for Pediatric Head Trauma: Do Patient and Hospital Characteristics Influence Who Gets Imaged?. Academic Emergency Medicine, 2010, 17, 694-700.	1.8	85
104	Relative Impact of Influenza and Respiratory Syncytial Virus in Young Children. Pediatrics, 2009, 124, e1072-e1080.	2.1	68
105	Pediatric Adverse Drug Events in the Outpatient Setting: An 11-Year National Analysis. Pediatrics, 2009, 124, e744-e750.	2.1	75
106	"Left Without Being Seen― A National Profile of Children Who Leave the Emergency Department Before Evaluation. Annals of Emergency Medicine, 2008, 52, 599-605.	0.6	48
107	Evaluation of Influenza Prevention in the Workplace Using a Personally Controlled Health Record: Randomized Controlled Trial. Journal of Medical Internet Research, 2008, 10, e5.	4.3	39
108	Emergency Care for Children in Pediatric and General Emergency Departments. Pediatric Emergency Care, 2007, 23, 94-102.	0.9	133

#	Article	IF	CITATIONS
109	The Value of Patient Self-report for Disease Surveillance. Journal of the American Medical Informatics Association: JAMIA, 2007, 14, 765-771.	4.4	52
110	Validation of Syndromic Surveillance for Respiratory Infections. Annals of Emergency Medicine, 2006, 47, 265.e1.	0.6	49
111	Lumbar Puncture Ordering and Results in the Pediatric Population: A Promising Data Source for Surveillance Systems. Academic Emergency Medicine, 2006, 13, 767-773.	1.8	3
112	Influenza and Other Respiratory Virus-Related Emergency Department Visits Among Young Children. Pediatrics, 2006, 118, e1-e8.	2.1	83
113	Association of Race/Ethnicity with Emergency Department Wait Times. Pediatrics, 2005, 115, e310-e315.	2.1	120
114	Adult Patient Visits to Children's Hospital Emergency Departments. Pediatrics, 2003, 111, 1268-1272.	2.1	19
115	Retropharyngeal Cellulitis in a 5-Week-Old Infant. Pediatrics, 2002, 109, e51-e51.	2.1	11